Health
New weight-loss shot shows major fat reduction, but experts urge caution
NEWYou can now listen to Fox News articles!
An experimental medication was shown to help boost weight loss by up to 20%, a study found.
Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes, according to a press release.
The drug was generally well-tolerated by the study participants.
An experimental medication was shown to help boost weight loss by up to 20%, a study found. (iStock)
The Phase 2 trial, which was funded by Eli Lilly, included 263 adults. After 48 weeks, they had lost between 9.5% and 20.1% of their body weight, compared to 0.4% for those taking the placebo.
Treatment with eloralintide was also linked to improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation, all of which can increase cardiometabolic risk, according to the researchers.
WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT
“The weight loss we saw in the study is clinically impactful,” lead study author Liana K. Billings, M.D., director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Skokie, Illinois, said in the press release.
“With this degree of weight loss in only 48 weeks, we see people having improvement or resolution in other conditions like hypertension, hyperlipidemia, osteoarthritis, sleep apnea and more weight-related conditions.”
Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes. (Getty Images)
“Furthermore, in the study, we did not see a nadir or plateau of weight loss, so I would expect weight loss to continue if the study continued for a longer duration. Additionally, up to 90% of participants on eloralintide improved by at least one BMI category,” she added.
The results were published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, earlier this month.
AMERICA’S FATTEST STATES REVEALED — AND HOW OZEMPIC IS CHANGING THE MAP
While popular GLP-1 drugs — including Ozempic, Wegovy, Mounjaro and Zepbound — work by mimicking the gut hormone GLP-1 (glucagon-like peptide-1), eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin.
Similar to GLP-1s, it helps to slow digestion, reduce appetite and control blood sugar after meals. It has not yet been FDA-approved for clinical use.
While GLP-1 drugs work by mimicking the gut hormone GLP-1, eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin. (iStock)
The biggest side effects noted for eloralintide were mild to moderate gastrointestinal symptoms and fatigue, the researchers noted. These effects were greater at higher doses.
“Obesity is a complex condition, and no single treatment works for everyone,” said Billings.
“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them.”
COULD GLP-1 WEIGHT-LOSS MEDICATIONS LIKE OZEMPIC BECOME THE ‘EVERYTHING DRUG’?
Based on the trial results, the reseachers plan to launch Phase 3 clinical studies for obesity treatment by the end of this year, the president of Lilly Cardiometabolic Health confirmed to Fox News Digital. The drug is also being evaluated for use in combination with GLP-1 medications.
Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, shared some concerns about the new anti-obesity agents being developed.
“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” a doctor said. (iStock)
“Between all the agents out there, there is no way any person cannot lose weight when coupled with progressive resistance training and attention to their daily macronutrient intake, even if only a little,” the doctor, who was not involved in the study, told Fox News Digital.
“Yet big pharma will continue to search for novel targets to introduce a new drug that will likely prove similarly, yet not more, efficacious than the current agents. There are enough agents out there to drive weight loss to a malnutrition status.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Osborn also noted that the lower cardiovascular risk associated with the drug was likely due to the participants losing body fat, which reduces the risk for all age-related diseases.
“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term.”
“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Sue Decotiis, M.D., a medical weight-loss doctor in New York City, also shared her thoughts on eloralintide’s potential as an alternative treatment.
“It seems that the more receptor systems that are influenced, the more weight a patient can lose,” she told Fox News Digital. “This is why tirzepatide (Mounjaro, Zepbound), which hits two receptors, induced more weight loss than Ozempic and Wegovy.”
“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them,” a researcher said. (iStock)
“In my practice, I witnessed significantly better results with tirzepatide when patients were switched from Ozempic.”
Hitting more receptors may be the answer for those patients who do not respond well or who “hit the wall” with simpler drugs, according to Decotiis, who also was not involved in the study.
“For long-term safety and results, peptide drugs show promise,” she said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Whitney Di Bona, in-house attorney and consumer safety advocate for Drugwatch, noted that while the Phase 2 results are “promising,” it is important to be cautious.
“These drugs have been used for years, but new safety concerns keep appearing,” the Florida-based expert told Fox News Digital. Some of those include a potentially serious eye condition, delayed stomach emptying, bowel obstruction and serious digestive problems, which have led to many lawsuits.
CLICK HERE FOR MORE HEALTH STORIES
“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term,” Di Bona advised. “Even with careful studies, some risks may only become clear after the drug is used by many people.”
Health
Heart disease threat projected to climb sharply for key demographic
NEWYou can now listen to Fox News articles!
A new report by the American Heart Association (AHA) included some troubling predictions for the future of women’s health.
The forecast, published in the journal Circulation on Wednesday, projected increases in various comorbidities in American females by 2050.
More than 59% of women were predicted to have high blood pressure, up from less than 49% currently.
The review also projected that more than 25% of women will have diabetes, compared to about 15% today, and more than 61% will have obesity, compared to 44% currently.
As a result of these risk factors, the prevalence of cardiovascular disease and stroke is expected to rise to 14.4% from 10.7%.
The prevalence of cardiovascular disease and stroke in women is expected to rise to 14.4% from 10.7% by 2050. (iStock)
Not all trends were negative, as unhealthy cholesterol prevalence is expected to drop to about 22% from more than 42% today, the report stated.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Dr. Elizabeth Klodas, a cardiologist and founder of Step One Foods in Minnesota, commented on these “jarring findings.”
“The fact that on our current trajectory, cardiometabolic disease is projected to explode in women within one generation should be a huge wake-up call,” she told Fox News Digital.
NEARLY 90% OF AMERICANS AT RISK OF SILENT DISEASE — HERE’S WHAT TO KNOW
“Hypertension, diabetes, obesity — these are all major risk factors for heart disease, and we are already seeing what those risks are driving. Heart disease is the No. 1 killer of women, eclipsing all other causes of death, including breast cancer.”
Cardiovascular disease is the leading cause of death for women in the U.S. and around the world. (iStock)
Klodas warned that heart disease starts early, progresses “stealthily,” and can present “out of the blue in devastating ways.”
The AHA published another study on Thursday revealing one million hospitalizations, showing that heart attack deaths are climbing among adults below the age of 55.
The more alarming finding, according to Klodas, is that young women were found more likely to die after their first heart attack than men of the same age.
DOCTOR SHARES 3 SIMPLE CHANGES TO STAY HEALTHY AND INDEPENDENT AS YOU AGE
“This is all especially tragic since heart disease is almost entirely preventable,” she said. “The earlier you start, the better.”
Children can show early evidence of plaque deposition in their arteries, which can be reversed through lifestyle changes if “undertaken early enough and aggressively enough,” according to the expert.
Moving more is one part of protecting a healthy heart, according to experts. (iStock)
Klodas suggested that rising heart conditions are associated with traditional risk factors, like smoking, high blood pressure, high cholesterol, diabetes, obesity and a sedentary lifestyle.
CLICK HERE FOR MORE HEALTH STORIES
Doctors are also seeing higher rates of preeclampsia, or high blood pressure during pregnancy, as well as gestational diabetes. Klodas noted that these are sex-specific risk factors that don’t typically contribute to complications until after menopause.
The best way to protect a healthy heart is to “do the basics,” Klodas recommended, including the following lifestyle habits.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Klodas especially emphasized making improvements to diet, as the food people eat affects “every single risk factor that the AHA’s report highlights.”
“High blood pressure, high blood sugar, high cholesterol, excess weight – these are all conditions that are driven in part or in whole by food,” she said. “We eat multiple times every single day, which means what we eat has profound cumulative effects over time.”
“Even a small improvement in dietary intake, when maintained, can have a massive positive impact on health,” a doctor said. (iStock)
“Even a small improvement in dietary intake, when maintained, can have a massive positive impact on health.”
The doctor also recommends changing out a few snacks per day for healthier choices, which has been proven to “yield medication-level cholesterol reductions” in a month.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Keep up that small change and, over the course of a year, you could also lose 20 pounds and reduce your sodium intake enough to avoid blood pressure-lowering medications,” Klodas added.
“Women should not view the AHA report as inevitable. We have power over our health destinies. We just need to use it.”
Health
Vanessa Williams, 62, Opens up About Weight Loss and HRT After Menopause
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Common vision issue linked to type of lighting used in Americans’ homes
NEWYou can now listen to Fox News articles!
Nearsightedness (myopia) is skyrocketing globally, with nearly half of the world’s population expected to be myopic by 2050, according to the World Health Organization.
Heavy use of smartphones and other devices is associated with an 80% higher risk of myopia when combined with excessive computer use, but a new study suggests that dim indoor lighting could also be a factor.
For years, scientists have been puzzled by the different ways myopia is triggered. In lab settings, it can be induced by blurring vision or using different lenses. Conversely, it can be slowed by something as simple as spending time outdoors, research suggests.
Nearsightedness occurs when the eyeball grows too long from front to back, according to the American Optometric Association (AOA). This physical elongation causes light to focus in front of the retina rather than directly on it, making distant objects appear blurry.
The study suggests that myopia isn’t caused by the digital devices themselves, but by the low-light environments where they are typically used. (iStock)
Researchers at the State University of New York (SUNY) College of Optometry identified a potential specific trigger for this growth. When someone looks at a phone or a book up close, the pupil naturally constricts.
COMMON VISION ISSUE COULD LEAD TO MISSED CANCER WARNING, STUDY FINDS
“In bright outdoor light, the pupil constricts to protect the eye while still allowing ample light to reach the retina,” Urusha Maharjan, a SUNY Optometry doctoral student who conducted the study, said in a press release.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“When people focus on close objects indoors, such as phones, tablets or books, the pupil can also constrict — not because of brightness, but to sharpen the image,” she went on. “In dim lighting, this combination may significantly reduce retinal illumination.”
High-intensity natural light prevents myopia because it provides enough retinal stimulation to override the “stop growing” signal, even when pupils are constricted. (iStock)
The hypothesis suggests that when the retina is deprived of light during extended close-up work, it sends a signal for the eye to grow.
In a dim environment, the narrowed pupil allows so little light through that the retinal activity isn’t strong enough to signal the eye to stop growing, the researchers found.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
In contrast, being outdoors provides light levels much brighter than indoors. This ensures that even when the pupil narrows to focus on a nearby object, the retina still receives a strong signal, maintaining healthy eye development.
CLICK HERE FOR MORE HEALTH STORIES
The team noted some limitations of the study, including the small subject group and the inability to directly measure internal lens changes, as the bright backgrounds used to mimic the outdoors made pupils too small for standard equipment.
Researchers believe that increasing indoor brightness during close-up work could be a simple, testable way to slow the global nearsightedness epidemic. (iStock)
“This is not a final answer,” Jose-Manuel Alonso, MD, PhD, SUNY distinguished professor and senior author of the study, said in the release.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“But the study offers a testable hypothesis that reframes how visual habits, lighting and eye focusing interact.”
The study was published in the journal Cell Reports.
-
World2 days agoExclusive: DeepSeek withholds latest AI model from US chipmakers including Nvidia, sources say
-
Massachusetts2 days agoMother and daughter injured in Taunton house explosion
-
Montana1 week ago2026 MHSA Montana Wrestling State Championship Brackets And Results – FloWrestling
-
Oklahoma1 week agoWildfires rage in Oklahoma as thousands urged to evacuate a small city
-
Louisiana5 days agoWildfire near Gum Swamp Road in Livingston Parish now under control; more than 200 acres burned
-
Technology6 days agoYouTube TV billing scam emails are hitting inboxes
-
Denver, CO2 days ago10 acres charred, 5 injured in Thornton grass fire, evacuation orders lifted
-
Technology6 days agoStellantis is in a crisis of its own making